Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Return on Sales (2016 - 2025)

Historic Return on Sales for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 0.1%.

  • Amicus Therapeutics' Return on Sales rose 1500.0% to 0.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 1900.0%. This contributed to the annual value of 0.11% for FY2024, which is 2700.0% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Return on Sales stood at 0.1%, which was up 1500.0% from 0.16% recorded in Q2 2025.
  • Amicus Therapeutics' Return on Sales' 5-year high stood at 0.1% during Q3 2025, with a 5-year trough of 1.08% in Q1 2022.
  • For the 5-year period, Amicus Therapeutics' Return on Sales averaged around 0.45%, with its median value being 0.44% (2024).
  • As far as peak fluctuations go, Amicus Therapeutics' Return on Sales skyrocketed by 4800bps in 2021, and later crashed by -1100bps in 2022.
  • Amicus Therapeutics' Return on Sales (Quarter) stood at 1.01% in 2021, then soared by 37bps to 0.63% in 2022, then soared by 54bps to 0.29% in 2023, then skyrocketed by 133bps to 0.1% in 2024, then grew by 4bps to 0.1% in 2025.
  • Its Return on Sales was 0.1% in Q3 2025, compared to 0.16% in Q2 2025 and 0.17% in Q1 2025.